Table 3.
Liver function at TACE refractoriness
Year | n | Child-Pugh class |
||
---|---|---|---|---|
A | B/C | |||
Ogasawara [23] | 2014 | 122 | 75% | 25% |
Arizumi [24] | 2014 | 56 | 80% | 20% |
OPTIMIS [25] | 2019 | 636 | 64% | 26% |
At the time of TACE refractoriness, liver function has already decreased, and there are many patients who are not good candidates for systemic therapy. TACE refractoriness is too late when considering systemic therapy.